Xcorporeal to Present at The William Blair 2008 Annual Small-Cap Growth Stock Conference on Tuesday, October 7th
October 06 2008 - 7:30AM
Business Wire
Xcorporeal, Inc. (AMEX:XCR) announced today that Dan Goldberger of
Xcorporeal will be presenting at The William Blair 2008 Annual
Small-Cap Growth Stock Conference, at The Waldorf Astoria Hotel in
New York City, on Tuesday, October 7, 2008 at 4:00 p.m. Eastern
Time. The Company�s presentation will also be webcast live and
archived for future reference, for 30 days, at
www.wsw.com/webcast/blair14/xcr/ and also available on the
Company�s website at www.xcorporeal.com. About Xcorporeal
Xcorporeal, Inc. is a medical device company developing an
innovative extra-corporeal platform technology to be used in
devices to replace the function of various human organs. The
platform leads to three initial products: a Portable Artificial
Kidney (PAK) for hospital based Renal Replacement Therapy, the
XCR-6 for home hemodialysis, and a Wearable Artificial Kidney (WAK)
for continuous ambulatory hemodialysis. For the hospital market,
Xcorporeal is developing a portable, multi-functional renal
replacement device that will offer cost-effective therapy for those
patients suffering from Acute Renal Failure, which causes a rapid
decline in kidney function. In the U.S., the disease affects more
than 200,000 patients annually with a mortality rate approaching
50%, according to a study published in the Clinical Journal of
American Society of Nephrology in 2006. The Company has completed a
functional prototype of the product, which is currently undergoing
bench testing, and anticipates submitting 510(k) filings, for the
device and attendant disposable components, with the Food and Drug
Administration (FDA) during 2009. The Company also plans to
commercialize the XCR-6, a home hemodialysis device, for the
chronic End Stage Renal Disease (ESRD) market, comprised of
patients in whom the kidneys have ceased to function. The Company�s
devices are intended to combine the best attributes of currently
marketed home hemodialysis machines to offer patients convenient,
durable and truly portable treatments at home. The Company believes
its devices will provide a cost-effective alternative to current
home treatment modalities, due to their ability to offer
hemodialysis without the need for large quantities of dialysate
fluid or purified water. The Company has also completed a
functional prototype of the XCR-6, which is currently undergoing
bench testing, and anticipates submitting a 510(k) with the FDA
during 2010. The Company�s WAK is also a device for the chronic
treatment of ESRD. The Company has successfully demonstrated a
prototype system that weighs less than 6 kg., is battery operated,
and can be worn by an ambulatory patient. This miniature, wearable
device is intended to enable continuous (up to 24 hours � 7 days
per week) renal replacement therapy at home. Increasing dialysis
time has previously been shown to reduce morbidity and improve
quality of life of ESRD patients. The WAK has been featured in
articles written by the Los Angeles Times, The Lancet, Kidney
International, and various other medical periodicals. Additional
Company information may be found on the Internet at:
www.xcorporeal.com. Forward-Looking Statements Except for
statements of historical fact, the matters discussed in this press
release are forward looking and made pursuant to the Safe Harbor
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements reflect numerous assumptions and
involve a variety of risks and uncertainties, many of which are
beyond the company's control that may cause actual results to
differ materially from stated expectations. These risk factors
include, among others, limited operating history, difficulty in
developing, exploiting and protecting proprietary technologies, the
risk that our technology may not be effective, uncertainty as to
the outcome of arbitration and legal proceedings, intense
competition and substantial regulation in the medical device
industry; and additional risks factors as discussed in the reports
filed by the Company with the Securities and Exchange Commission,
which are available on its website at http://www.sec.gov.
Xcorporeal, Inc. (AMEX:XCR)
Historical Stock Chart
From May 2024 to Jun 2024
Xcorporeal, Inc. (AMEX:XCR)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Xcorporeal, Inc. (American Stock Exchange): 0 recent articles
More Xcorporeal, Inc. News Articles